Immunic, Inc. (NASDAQ:IMUX) Receives $7.50 Average PT from Analysts

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven analysts that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $7.50.

IMUX has been the topic of a number of research reports. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Immunic in a research note on Wednesday, June 25th. B. Riley reissued a "buy" rating and issued a $5.00 price objective (down previously from $6.00) on shares of Immunic in a research report on Friday, May 23rd. William Blair reissued an "outperform" rating on shares of Immunic in a research report on Friday, May 16th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research report on Thursday, May 1st.

Hedge Funds Weigh In On Immunic

Several institutional investors and hedge funds have recently modified their holdings of IMUX. Invesco Ltd. acquired a new position in shares of Immunic in the fourth quarter valued at $37,000. Barclays PLC acquired a new position in shares of Immunic in the fourth quarter valued at $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Immunic by 90.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock valued at $205,000 after purchasing an additional 96,894 shares during the last quarter. Bridgeway Capital Management LLC increased its holdings in shares of Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after purchasing an additional 22,200 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after purchasing an additional 152,726 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Price Performance

IMUX traded down $0.01 during trading on Thursday, reaching $0.93. The company had a trading volume of 668,229 shares, compared to its average volume of 1,065,974. Immunic has a 12 month low of $0.56 and a 12 month high of $2.11. The business's fifty day moving average price is $0.83 and its 200 day moving average price is $0.97. The company has a market cap of $89.26 million, a P/E ratio of -0.76 and a beta of 1.38.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.25). As a group, sell-side analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.